Takeda Pharmaceutical Company announced that results from the primary endpoint analysis of the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue vaccine candidate (TAK-003) were published in the New England Journal of Medicine. Takeda’s dengue vaccine candidate demonstrated protection against virologically-confirmed dengue (VCD), the trial primary endpoint, in children ages four to 16 years. Vaccine efficacy (VE) was 80.2 per cent (95 per cent confidence interval [CI]: 73.3 per cent to 85.3 per cent; p<0.001) in the 12-month period after the second dose, which was administered three months after the first dose. Similar degrees of protection were seen in individuals who had and had not been previously infected with dengue based on planned exploratory analyses of secondary endpoints (VE: 82.2 per cent [95 per cent CI: 74.5 per cent to 87.6 per cent] vs. VE: 74.9 per cent [95 per cent CI: 57.0 per cent to 85.4 per cent], respectively). Other exploratory analyses showed a 95.4 per cent reduction in dengue-associated hospitalisations (95 per cent CI: 88.4 per cent to 98.2 per cent). Efficacy against severe disease could not be assessed due to the limited number of cases. Onset of protection was seen after the first dose, with 81 per cent VE (95 per cent CI: 64.1 per cent to 90.0 per cent) between the first and second doses.
Takeda’s dengue vaccine candidate was generally well tolerated, and no important safety risks have been observed to date. The observed safety profile was consistent with results reported in previous studies of TAK-003.1,2,3,4 The TIDES trial will continue to assess safety and efficacy in study subjects for a total of four and a half years.
ãã®èšäºã¯ Express Pharma ã® November 16-30, 2019 çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã8,500 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã ?  ãµã€ã³ã€ã³
ãã®èšäºã¯ Express Pharma ã® November 16-30, 2019 çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã8,500 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã? ãµã€ã³ã€ã³
Achieving Aatmanirbharta In APIs Are We On The Right Track?
As India gears up to celebrate its 75th Independence Day, self reliance in APIs remains a key goal for the pharma sector. AatmaNirbharta will be crucial for the sector as it continues to protect the country from the existing and emerging health threats
Yokogawa launches OpreX Data Model Broker
A plant data transformation platform, OpreX automatically verifies discrepancies and inconsistencies in data to improve efficiency in plant construction and operation
Understanding the nuances of generics injectables
At a webinar, explaining the West Pharma's AccelTRA Components Program, industry experts explained why the use of glass vials and stoppers as primary container closure systems (CCS) has become crucial
Trending in nutraceuticals: Science meets sustainability
Zeljko Pockaj, Vice President, Global Pharmaceutical Industry, mentions the key trends that are believed to drive innovations and formulations for nutraceuticalsâ development around the globe
The growth of e-pharmacies in India
Rahul Nath Choudhury, Research fellow, ICWA, explains what motivates people in the pharma industry to invest into e-pharmacies, along with various other growth factors associated with these
Xylitol and Maltitol: Low-calorie sugar alternatives
Polyols like Xylitol and Maltitol offer important health benefits. Unlike general sugar-free sweeteners, these do not have any bitter-after taste
Single-use TC gaskets and their importance
Depending on the application, gaskets are manufactured by different types of Material of Construction (MOC) such as Silicone, EPDM, Viton (FKM), Nitrile, Neoprene, PTFE, etc.
It's important to enhance customer experience so that existing customers are more loyal
Sheshgiri Kamath, CEO and co-founder, Kapture CRM, expands on why it is important for pharma companies to enhance customer experience, and how the right CRM solution can help companies to identify, address and manage customer expectations more effectively, in an interaction with Viveka Roychowdhury
From HIV to COVID-19: The role of liposomal nanotechnology as an NDDS of choice
Arun Kedia, Managing Director,VAV Life Sciences, elaborates how NDDS have proved to be beneficial with applications across various medical therapies ranging from HIV to cancer to COVID-19 treatment
Ensuring pharma compliance with testo data loggers
Testo data loggers can be used to test the optimum conditions for specific products or surroundings